Clinical Characteristics And Health Care Resources In Patients Treated With Oral Anticoagulants: Evidences From Italian Administrative Databases
Authors Degli Esposti L, Andretta M, Di Pasquale G, Gambera M, Saragoni S, Perrone V, Buda S
Received 22 May 2019
Accepted for publication 26 September 2019
Published 11 October 2019 Volume 2019:15 Pages 429—437
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Nicola Ludin
Peer reviewer comments 3
Editor who approved publication: Dr Konstantinos Tziomalos
L Degli Esposti,1 M Andretta,2 G Di Pasquale,3 M Gambera,4 S Saragoni,1 V Perrone,1 S Buda1
1CliCon S.r.l. Health, Economics & Outcomes Research, Ravenna, Italy; 2Local Pharmaceutical Service, Verona Local Health Authority, Verona, Italy; 3Department of Cardiology, Maggiore Hospital, Bologna, Italy; 4Local Pharmaceutical Service, Bergamo Local Health Authority, Bergamo, Italy
Correspondence: V Perrone
CliCon S.r.l, Health, Economics and Outcomes Research, Via Salara, 36, Ravenna 48100, Italy
Tel +39 054438393
Fax +39 0544212699
Objectives: 1) To evaluate anticoagulation treatment patterns and health care resource use in adult patients with a discharge diagnosis of non-valvular atrial fibrillation (NVAF) in an Italian real-world setting and 2) to describe the characteristics of NVAF patients in relation to treatment.
Design: A retrospective cohort study in a “real-world” setting.
Setting: Data were analysed by integrating administrative databases that included approximately 2,000,000 individuals assisted by the National Health System from two Italian Local Health Units.
Participants: All adult patients with at least one hospital discharge or ≥2 outpatient visits with a diagnosis code for NVAF from 1/01/2011 to 31/12/2015 were included.
Main outcome measures: Anticoagulation treatment patterns, health care resource use and major bleeding events that occurred during the follow-up period were evaluated.
Results: 32,863 NVAF patients were included, of whom 7,831 had at least one prescription of oral anticoagulants. Among them, 6,876 patients were vitamin K antagonists (VKA) users and 955 were non-vitamin K antagonist oral anticoagulant (NOAC) users at index date (ID). During the follow-up period, the use of antiplatelet drugs was higher among VKA-naïve users than the NOAC-naïve users. Among NOAC users, 76.1% showed an adherence level ≥80% during follow-up. The rate of bleeding events resulted higher for VKA patients compared to NOAC patients. The unadjusted incidence rate was 10.46 per 1000 person-year for VKA patients and 4.55 per 1,000 person-years for NOAC patients. The overall annual cost (in term of drugs, hospitalisations and outpatient specialist services) was € 5,156.13 for VKA and € 4,630.57 for NOAC.
Conclusion: This unselected cohort study, on NVAF patients being prescribed oral anticoagulants, highlights that VKA was largely prescribed and the great majority of patients on NOACs were adherent to treatment. Most of the OAC patients still received antiplatelet agents in combination, and in NOAC patients, we registered a lower number of bleeding events compared with VKA.
Keywords: non-valvular atrial fibrillation, vitamin K antagonists, non-vitamin K antagonist oral anticoagulants, anticoagulation treatment patterns, real-world setting
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]